Coenzyme Q10

Coenzyme Q10 stabilizes Heartbeat in persons afflicted with Arrhythmia. Coenzyme Q10 prevents Atherosclerosis (by preventing the oxidation of LDL Cholesterol).

Coenzyme Q10 assists the heart to function normally in the presence of Blood Clots.  39% of people afflicted with Hypertension are found to be deficient in CoQ10.

Supplemental Coenzyme Q10 counteracts the severe CoQ10 deficiency that occurs in the heart in conjunction with most Cardiovascular Diseases.

Coenzyme Q10 alleviates Congestive Heart Failure (CHF) and most people afflicted with CHF are found to exhibit a Coenzyme Q10 deficiency. Coenzyme Q10 improves the condition of 91% of heart attack patients within 30 days.

Coenzyme Q10 improves the heart's ability to survive and produce energy in Hypoxia (limited Oxygen) situations such as: high altitudes, clogged arteries, Angina.

Coenzyme Q10 lowers Blood Pressure in people afflicted with Hypertension (by normalizing the body's Sodium:Potassium ratio) 

39% of people afflicted with Hypertension are found to be deficient in CoQ10. 
Coenzyme Q10 normalizes Heart function in people with Mitral Valve Prolapse.

Coenzyme Q10 reduces the viscosity of Blood in people  with Ischaemic Heart Disease 

Coenzyme Q10 facilitates the elimination of Candida albicans.    to order

People who are infected with the HIV virus and who are also deficient in Coenzyme Q10 progress more rapidly to full-blown AIDS than do people with optimal CoQ10 levels. Thus, AIDS was associated with CoQ10 levels that were severely and significantly depressed, while HIV-positive people without symptoms had normal levels that declined as they progressed to ARC, and further declined as they developed full-blown AIDS. Further studies showed that ARC patients on CoQ10 therapy remained free of opportunistic infections and didn't progress to AIDS over a period of more than four years].

Coenzyme Q10 alleviates Allergies and people afflicted with severe allergies almost always exhibit lower-than-normal blood levels of CoQ10.  Coenzyme Q10 can double the body's level of protective Antibodies.

Coenzyme Q10 increases the life expectancy of people afflicted with these forms of Cancer: Breast Cancer, Lung Cancer, Laryngeal Cancer, Pancreatic Cancer, Prostate Cancer. Preliminary research indicates that CoQ10 suppresses the proliferation of Cancer cells and boosts the Immune System chemicals that attack Cancer cells.  

Coenzyme Q10 greatly enhances the general function of the Immune System.

Coenzyme Q10 enhances the function of Macrophages.

Coenzyme Q10 increases the body's resistance to Viruses.

Coenzyme Q10 improves athletic performance (by increasing the body's production of energy via Adenosine Triphosphate) [improvement of 12-28% measured after 4 weeks using 30 mg per day].

Coenzyme Q10 alleviates Diabetes Mellitus [8% of Diabetes sufferers are deficient in CoQ10- Supplements reduce blood sugar levels by at least 20% in 36% of Diabetes Mellitus sufferers and reduces blood sugar levels by at least 30% in 31% of Diabetes Mellitus sufferers

Coenzyme Q10 increases Energy in both sedentary individuals and in athletes.

Coenzyme Q10 helps to prevent the damage to muscles that can occur as a result of intensive exercise.  Supplemental Coenzyme Q10 alleviates the impaired aerobic function that is associated with fatigue.

Coenzyme Q10 prevents the build-up of excessive serum levels of Ketones (Ketosis) [diabetes sufferers' Ketone levels fell by at least 30% in 60% of subjects receiving CoQ10]. 
Coenzyme Q10 prevents the (free radical induced) oxidation of LDL Cholesterol 

Obese people are often deficient in Coenzyme Q10 - CoQ10 supplementation accelerates weight loss in obesity cases in which the person is found to be deficient in CoQ10 [52% of obesity sufferers are deficient in Coenzyme Q10 and these deficient people lose an average of 8 kg of additional weight over an 9 week period when supplemented with CoQ10].

Coenzyme Q10 reduces the extent of damage caused to the muscles by intensive 

People afflicted with Muscular Dystrophy are usually found to be deficient in Coenzyme Q10 and supplemental Coenzyme Q10 (often) alleviates Muscular Dystrophy [Muscular Dystrophy patients administered 100 mg of CoQ10 per day for 3 months demonstrated significant improvement in cardiac output, stroke volume, physical wellbeing and definite improvement in exercise tolerance, leg pain, leg function and fatigue].

Coenzyme Q10 dramatically halts the progression of Periodontal Disease and usually totally heals the damage already done, including the regrowth of previously atrophied tissue - Coenzyme Q10 improves the supply of Coenzyme Q10 to deficient Gum. 

Coenzyme Q10 dramatically halts the progression of Gingivitis and can totally heal the damage [Co Q10 can eliminate Gingivitis in under 5 days in most Gingivitis sufferers @ 50-75 mg per day].

High doses of supplemental Coenzyme Q10 are an effective therapy for Psoriasis.

(Coenzyme Q10 helps to prevent the Neuron damage that leads to Alzheimer's Disease [deficiencies in CoQ10-dependent enzymes may be implicated in the development of the neuronal death that results in Alzheimer's. Reversal of mental function deterioration has been documented in several studies utilizing supplemental CoQ10, including documented improvements in mental function in people with genetically-confirmed Alzheimer's Disease].

Coenzyme Q10 helps to prevent the Neuron damage that leads to Parkinson's.


References                                to order

Folkers, K., et al. Biochemical deficiencies of Coenzyme Q10 in HIV-infection and exploratory treatment. Biochemical and Biophysical Research Communications. 153(2):888-896, 1988.

· Folkers, K., et al. Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun. 192(1):241-245, 1993.

· Folkers, K., et al. Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun. 176(2):786-791, 1991.

· Langsjoen, P. H., et al. Treatment of patients with human immunodeficiency virus infection with coenzyme Q10. In: Biomedical and Clinical Aspects of Coenzyme Q, Folkers, K., et al. (editors). Volume 6, 1991, pages 409-415.

· Tanner, H. A. Energy transformations in the biosynthesis of the immune system: their relevance to the progression and treatment of AIDS. Medical Hypotheses. 38(4):315-321, 1992.

· Imagawa, M. Megavitamin therapy (Coenzyme Q10 and vitamin B6) in Alzheimer’s disease and senile dementia of Alzheimer type. In: Basic, Clinical and Therapeutic Aspects of Alzheimer’s and Parkinson’s Diseases, Volume 2, by Nagatsu, et al, pages 489-491, Plenum Press, New York, 1990.

· Kamikawa T. et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. American Journal of Cardiology. 56:247, 1985.

· Okada, K., et al. Cell injury by antineoplastic agents and influence of coenzyme Q10 on cellular potassium activity and potential difference across the membrane in rat liver cells. Cancer Research. 40:1663-1667, 1980.

· Beyer, R. E. An analysis of the role of coenzyme Q10 in free radical generation and as an antioxidant. Biochem Cell Biol. 70:390-403, 1992.

· Linnane, A. 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q10. Ancona, Italy, 1996. Reported In: Life Extension. 2(11):42, 1996.

· Vanfraechem, J. H. P., et al. Coenzyme Q10 and physical performance, in Folkers, K., Yamamura, Y., Eds., Biomedical and Clinical Aspects of Coenzyme Q. 3:235-241, 1981.

· Yikoski, T., et al. The effect of coenzyme Q10 on exercise performance of cross-country skiers. Molecular Aspects of Medicine (United Kingdom). 18(Supplement):S283-S290, 1997.

Summary: In a double-blind study, cross-country skiers were administered 90 mg of Coenzyme Q10 per day. All measures of physical performance increased and during supplementation 94% of athletes considered that their treatment had been beneficial in improving their performance vs. 33% in placebo groups.

· Bliznakov, E., et al. Coenzymes Q: stimulants of the phagocytic activity in rats and immune response in mice. Experientia. 26:953-954, 1970.

· Gaby, A. R. The role of coenzyme Q10 in clinical medicine. Part II. Cardiovascular disease, hypertension, diabetes mellitus and infertility. Alt Med Rev. 1(3):168-175, 1996.

· Mellstedt, H., et al. A deficiency of coenzyme Q10 (CoQ10) in cancer patients in Sweden. In: Eighth International Symposium on Biomedical and Clinical Aspects of Coenzyme Q. The Molecular Aspects of Medicine. 1994.

· Folkers, K., et al. Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun. 192(1):241-245, 1993.

· Lockwood, K., et al. Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional anitoxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med. 15(Supplement):S231-S240, 1994.

· Lockwood K., et al. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun. 199(3):1504-1508, 1994.

· Lockwood, K., et al. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochemical and Biophysical Research Communications. 212(1):172-177, 1995.

· Mortensen, S. A. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Investig (Germany). 71(8)(Supplement):S1126-S1133.

· Dean, W., M. D., et al. Mitochondrial nutrition, aging and cognition. Smart Drug News. 5(2):1-7, 1996.

· Folkers, K., et al. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proceedings of the National Academy of Sciences. 82:901, 1985.

· Gaby, A. R. The role of coenzyme Q10 in clinical medicine. Part II. Cardiovascular disease, hypertension, diabetes mellitus and infertility. Alt Med Rev. 1(3):168-175, 1996.

· Langsjoen, P. H., et al. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci. 82:4240, 1985.

· Langsjoen, P. H., et al. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr. 66:583-593, 1988.

· Langsjoen, P. H, et al. A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10. Int J Tissue React. 12:169-171; 1990.

· Mortensen, S. A. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clinical Investigator. 71:S116-S123, 1993.

· Greenberg, A., et al. Coenzyme Q10: A new drug for cardiovascular disease. Journal of Clinical Pharmacology. 30: 596-608, 1990.

· Shults, C. W., et al. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 42(2):261-264, 1997.

· Baggio, E., et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med. 15(Supplement):S287-S294, 1994.

· Folkers, K. Heart failure is a dominant deficiency of coenzyme q10 and challenges for future clinical research on CoQ10. Clinical Investigator. 71:S51-S54, 1993.

· Hofman-Bang, C., et al. Coenzyme Q10 as an adjunctive treatment of congestive heart failure. J Am Coll Cardiol. 19:216A, 1992.

· Lampertico, M., et al. Italian multicenter study on the efficacy and safety of coenzyme Q10 as adjuvant therapy in heart failure. Clinical Investigator. 71:S129-S133, 1993.

· Morisco, C., et al. Effect of coenzyme Q10 therapy in patients with congestive heart failure: A long-term multicenter randomized study. Clin Invest. 71(Supplement 8):S134-S136, 1993.

· Mortensen, S. A., et al. Coenzyme Q10: Clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 12 (3):155-162, 1990.

· Ursini, T., et al. Coenzyme Q10 treatment of heart failure in the elderly: Preliminary results. In: Biomedical and Clinical Aspects of Coenzyme Q. Volume 6. Folkers, K., et al (editors). Elsevier, Amsterdam, The Netherlands, pages 473-480, 1991.

· Kishi, T., et al. Bioenergetics in clinical medicine. XI. Studies on coenzyme Q and diabetes mellitus. J Med. 7:307, 1976.

· Shigeta, Y., et al. Effect of coenzyme Q10 treatment on blood sugar and ketone bodies of diabetics. J Vitaminology. 12:293-298, 1966.

· Langsjoen, P. H., et al. Long term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. The American Journal of Cardiology. 65:521-523, 1989.

· Mortensen, S. A., et al Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 12:155-162,1990.

· Beal, F. M. Neuroprotective effects of CoQ10. 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q10. Ancona, Italy, 1996.

· Choe, J. Y., et al. Prevention of coenzyme Q10 of the electrocardiographic changes induced by adriamycin in rats. Res Commun Chem Pathol Pharmacol. 23:199-202, 1979.

· Choe, J. Y., et al. Study of the combined and separate administration of doxorubicin and coenzyme Q10 on mouse cardiac enzymes. Res Commun Chem Pathol Pharmacol. 24:595-598, 1979.

· Combs, A. B., et al. Reduction by coenzyme Q10 of the acute toxicity of adriamycin in mice. Res Commun Chem Pathol Pharmacol. 18:565, 1977.

· Cortes, E. P., et al. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat. Rep. 62:887-891, 1978.

· Zbinden, G., et al. Study of coenzyme Q in toxicity of adriamycin. Clinical Aspects of Coenzyme Q, pages 219-228, Elsevier/North Holland Biomedical Press. 1977.

· Porter, D. A., et al. The effect of oral coenzyme Q10 on the exercise tolerance of middle-aged, untrained men. Int J Sports Med. 16(7):421-427, 1995.

· Yamabe, H., et al. In: Biochemical and Clinical Aspects of Coenzyme Q. Folkers, K., et al (editors). Elsevier/North Holland Biochemical Press, 1991, pages 535-540.

· Zeppilli, P., et al. In: Biochemical and Clinical Aspects of Coenzyme Q. Folkers, K., et al (editors). Elsevier/North Holland Biochemical Press, 1991, pages 541-545.

· Fiorella, P. L., et al. In: Biochemical and Clinical Aspects of Coenzyme Q. Folkers, K., et al. (editors). Volume 6. Biochemical Press. Elsevier, North Holland, 1991.

· Shimomura, Y., et al. Protective effect of coenzyme Q10 on exercise-induced muscular injury. Biochem Biophys Res Commun. 176:349-355, 1991.

· Wyss, V., et al. In: Highlights in Ubiquinone Research. Lenaz, G., et al. (editors). Taylor & Francis, New York, USA, 1990, pages 303-306.

· Yikoski, T., et al. The effect of coenzyme Q10 on exercise performance of cross-country skiers. Molecular Aspects of Medicine (United Kingdom). 18(Supplement):S283-S290, 1997.

Summary: In a double-blind study, cross-country skiers were administered 90 mg of Coenzyme Q10 per day. All measures of physical performance increased and during supplementation 94% of athletes considered that their treatment had been beneficial in improving their performance vs. 33% in placebo groups.

· Langsjoen, H., et al. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med. 15(Supplement):S165-S175, 1994.

· Mortensen, S. A., et al. Long term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drugs Exp Clin Res. 11(8):581-593, 1985.

· Folkers, K., et al. Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun. 176(2):786-791, 1991.

· Folkers, K., et al. The activities of coenzyme Q10 and vitamin B6 for immune response. Biochem-Biophys Res Commun. 193(1):88-92, 1993.

· Bargossi, A. M., et al. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med. 15(Suppl.):S187-S193, 1994.

· Folkers, K., et al. Lovastatin decreases coenzyme Q levels in humans. Proceedings of the National Academy of Sciences. 87, 1990.

· Willis, R. A., et al. Lovastatin decreases coenzyme Q levels in rats. Proceedings of the National Academy of Sciences. 87:8928-8930, 1990.

· Feigin, A., et al. Assessment of coenzyme Q10 tolerability in Huntington’s disease. Mov Disord. 11(3):321-323, 1996.

· Koroshetz, W. J., et al. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10. Annals of Neurology. 41(2):160-165, 1997.

· Digiesi, V., et al. Mechanism of the action of coenzyme Q10 in essential hypertension. Curr Ther Res. 51:668-672, 1992.

· Digiesi, V., et al. Coenzyme Q10 in essential hypertension. Mol Aspects Med. 15(Supplement):S257-S263, 1994.

· Gaby, A. R. The role of coenzyme Q10 in clinical medicine. Part II. Cardiovascular disease, hypertension, diabetes mellitus and infertility. Alt Med Rev. 1(3):168-175, 1996.

· Langsjoen, P., et al. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med. 15(Supplement):S265-S272, 1994.

· Yamagami, T., et al. Bioenergetics in clinical medicine. Studies on coenzyme Q10 and essential hypertension. Research Communications in Chemical Pathology and Pharmacology. 11(2):273-278, 1975.

· Yamagami, T., et al. Bioenergetics in clinical medicine. VIII. Administration of coenzyme Q10 to patients with essential hypertension. Research Communications in Chemical Pathology and Pharmacology. 14(4):721-727, 1976.

· Folkers, K., et al. Increase in levels of IgG in serum of patients treated with Coenzyme Q10. Res Commun Chem Pathol Pharmacol. 38:335, 1982.

· Folkers, K., et al. Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun. 192(1):241-245, 1993.

· Bliznakov, E., et al. Coenzymes Q: stimulants of the phagocytic activity in rats and immune response in mice. Experientia. 26:953-954, 1970.

· Folkers, K., et al. Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res. 11:539-545, 1985.

· Kato T., et al. Reduction of blood viscosity by treatment with coenzyme Q10 in patients with ischemic heart disease. International Journal of Clinicial Pharmacology Ther Toxicol. 28(3):123-6, 1990.

· Coles, S., & Harris, S. B. Co-enzyme Q-10 and life extension. In: Advances in Anti-Aging Medicine. Volume 1. Dr. Ronald M. Klatz (editor), 1996.

· Brude, I. R., et al. Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants. Arterioscler Thromb Vasc Biol. 17(11):2576-2588, 1997.

· Saiki, I., et al. Macrophage activation with ubiquinones and their related compounds in mice. Int J Vit Nutr Res. 53:312, 1983.

· Langsjoen, H., et al. Usefulness of coenzyme Q10 in clinical cardiology: a long term study. Mol Aspects Med. 15(Suppl):165-174, 1994.

· Oda, T., et al. Effect of coenzyme Q10 on the stress-induced decrease of cardiac performance in pediatric patients with mitral valve prolapse. Jap Circ J. 48:1387, 1994.

· Beal, F. M. Neuroprotective effects of CoQ10. 9th International Symposium on Biomedical and Clinical Aspects of Coenzyme Q10. Ancona, Italy, 1996.

· Fiorella, P. L., et al. In: Biochemical and Clinical Aspects of Coenzyme Q. Folkers, K., et al. (editors). Volume 6. Biochemical Press. Elsevier, North Holland, 1991.

· Shimomura, Y., et al. Protective effect of coenzyme Q10 on exercise-induced muscular injury. Biochem Biophys Res Commun. 176:349-355, 1991.

· Wyss, V., et al. In: Highlights in Ubiquinone Research. Lenaz, G., et al. (editors). Taylor & Francis, New York, USA, 1990, pages 303-306.

· Folkers, K., et al. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proceedings of the National Academy of Science. 82:4513, 1985.

· Folkers, K., et al. Two successful double-blind trials with coenzyme Q10 (vitamin Q
10) on muscular dystrophies and neurogenic atrophies. Biochem Biophys Acta. 1271:281-286, 1975.

· Scholler, J., et al. Response of mice with genetic dystrophy to therapy with coenzyme Q. Int Z Vitaminforsch. 38:369-375, 1968.

· van Gaal, L., et al. Exploratory study of coenzyme Q10 in obesity. In: Biomedical and Research Aspects of Coenzyme Q, Vol 4. Folkers, K., & Yamura (eds.). Elsevier Science Publishers. Amsterdam, 1984, pp. 369-373.

· Dunlop, I. S., et al. Reversible ophthalmoplegia in CPEO. Aust NZ J Ophthalmol. 23(3):231-234, 1995.

· Shults, C. W., et al. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 42(2):261-264, 1997.

· Hanioka, T., et al. Effect of topical applications of coenzyme Q10 on adult periodontitis. Mol Aspects Med. 15(Suppl.):S241-S248, 1994.

· Hansen, I. L., et al. Bioenergetics in clinical medicine, IX, Gingival and leukocytic deficiencies of coenzyme Q10 in patients with periodontal disease. Res Commun Chem Pathol Pharmacol. 14:729, 1976.

· Littaru, G. P., et al. Deficiency of coenzyme Q10 in gingival tissue from patients with periodontal disease. Proc Natl Acad Sci. 68:2332, 1971.

· Nakamura, R., et al. Deficiency of conezyme Q in gingiva of patients with periodontal disease. Int J Vit Nutr Res. 43:84, 1973.

· Nakamura, R., et al. Study of CoQ10-enzymes in gingiva from patients with periodontal disease and evidence for a deficiency of coenzyme Q10. Proc Natl Acad Sci. 71:1456, 1974.

· Shizukuishi, S., et al. Therapy by coenzyme Q10 of experimental periodontitis in a dog model supports results of human periodontitis therapy. Biomedical and Clinical Aspects of Coenzyme Q, Vol 4. Folkers, K. and Yamamura, Y. (eds.). Elsevier Science Publ, Amsterdam, 1984, pp. 153-162.

· Tsunemitsu, A., et al. Effect of coenzyme Q administration on hypercitricemia of patients with periodontal disease. J Dental Res. 46:1382, 1967.

· Wilkinson, E. G., et al. Bioenergetics in clinical medicine, II, Adjunctive treatement with coenzyme Q in periodontal therapy. Res Commun Chem Pathol Pharmacol. 12(1):111, 1975.

· Wilkinson, E. G., et al. Treatment of periodontal and other soft tissue diseases of the oral cavity with coenzyme Q. Biomedical and Clinical Aspects of Coenzyme Q, Vol 1. Folkers, K and Yamamura, Y (eds.). Elsevier/North-Holland Biomedical Press, Amsterdam, 1977, pp. 251-265.

· Bliznakov, E., et al. Coenzymes Q: stimulants of the phagocytic activity in rats and immune response in mice. Experientia. 26:953-954, 1970.

· Casey, A. C., et al. Effect and structure-activity relationship of the coenzymes Q on the phagocytic rate of rats. Chem Biol Interact. 5:1-12, 1972.

· Mizuno, M., et al. Effects of oral supplementation of coenzyme Q10 on 21P-NMR detected skeletal muscle energy metabolism in middle-aged post-polio subjects and normal volunteers. Molecular Aspects of Medicine (United Kingdom). 18(Supplement):S291-S298, 1997.

· Folkers, K., et al. Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun. 176(2):786-791, 1991.